NewslettersHuman Immunology NewsTravere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA NephropathyBy Danielle Corrigan - May 17, 2022078Travere Therapeutics, Inc. announced the US FDA has accepted and granted Priority Review of its New Drug Application under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy.[Travere Therapeutics, Inc.]Press Release